TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32736141
Drug: Control (C)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (C) rinsing with saline solution for 90 seconds
Study: 34580096
Drug: Temocillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocillin (2 g three times a day)
Study: 34580096
Drug: Carbapenem (meropenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbapenem (meropenem 1 g three times a day or ertapenem 1 g once daily)
Study: 32747013
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus sorafenib (bevacizumab 5 mg/kg IV every 2 weeks, sorafenib 200 mg bid 5 days-on/2 days-off)
Study: 34655547
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol eye drops administered twice daily
Study: 32210440
Drug: TGF‐?RI/ALK5 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF‐?RI/ALK5 inhibitor galunisertib
Study: 36059921
Drug: Promethazine 12.5
Normalized name: promethazine 12.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 12.5 mg and dexamethasone 8 mg
Study: 32941872
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy for 23 months after 1 month of ticagrelor combined with aspirin
Study: 36999409
Drug: Standard dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dual antiplatelet therapy (DAPT) for 12 months
Study: 32584909
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning (ML) model for predicting obstructive CAD
Study: 32584909
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning (ML) model for revascularization
Study: 32584909
Drug: Removal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removal of imaging variables from ML model
Study: 35785559
Drug: Needle acupuncture
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle acupuncture (10-week bilateral treatment of ST34, EX–LE12, and EX–LE8)
Study: 34373044
Drug: safinamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: safinamide (50 mg/day) for 3 months
Study: 35229713
Drug: Personalised hip
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised hip therapy (individualised physiotherapist-led programme of conservative care)
Study: 33682457
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein intake (∼1.0 g·kg‐1·day‐1) during resistance training
Study: 33682457
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein intake (∼1.6 g·kg‐1·day‐1) during resistance training
Study: 32658754
Drug: National protocol:
Approvals — FDA: no, EMA: no, PMDA: no
Description: National protocol: initial dose of 100 ml followed by 100 ml 6th hourly until 20WBCT was negative or 300 ml of ASV was given, whichever was earlier
Study: 32658754
Drug: Current protocol:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current protocol: 70 ml followed by 30 ml every 6th hourly until two consecutive 20WBCT were negative
Study: 32658754
Drug: National ASV
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: National ASV dosing protocol
Study: 32975705
Drug: Gels containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gels containing 400 μM EGCG, 0.012% chlorhexidine, 1 mM FeSO4, 1.23% F (NaF)
Study: 32516291
Drug: Gliclazide 30
Normalized name: gliclazide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide 30 mg/day
Study: 32012166
Drug: Reciprocating single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reciprocating single file followed by matching-taper single-cone filling
Study: 33151847
Drug: Immersive 360°
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersive 360° video viewed through tablets
Study: 36209081
Drug: higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: higher dose of nabiximols
Study: 33390421
Drug: Intensive exercise
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive exercise plus 5 mg (up to 10 mg) of dapagliflozin daily (IT group)
Study: 35147302
Drug: 3.6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g/day n‐3‐PUFA
Study: 33675013
Drug: Home-based strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based strength exercise (twice weekly for 10 weeks) with educational materials, exercise equipment (dumbbells, resistance bands), and video coaching support.
Study: 32978076
Drug: Clarithromycin-naproxen-oseltamivir combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin-naproxen-oseltamivir combination therapy
Study: 36455504
Drug: FTD/TPI (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTD/TPI (35 mg/m2 twice daily days 1‐5 and 8‐12, 28‐day cycle)
Study: 32479701
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficient (25(OH)D <50nmol/L)
Study: 32479701
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D sufficient (25(OH)D ≥50nmol/L)
Study: 36352326
Drug: Psychiatric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric treatment initiation after March 2020
Study: 33452295
Drug: beta-blocker (timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker (timolol maleate) and/or prostaglandin analog (latanoprost)
Study: 33947390
Drug: pemafibrate 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: pemafibrate 0.1 mg/day
Study: 33947390
Drug: pemafibrate 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: pemafibrate 0.2 mg/day
Study: 33947390
Drug: pemafibrate 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: pemafibrate 0.4 mg/day
Study: 33947390
Drug: pemafibrate (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: pemafibrate (all doses)
Study: 33250209
Drug: Eptinezumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptinezumab (all doses)
Study: 34129855
Drug: Androgen-deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen-deprivation therapy (ADT) alone
Study: 33327340
Drug: Electroacupuncture (EA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA), administered 2 times a week for 4 weeks.
Study: 36103719
Drug: Electrical vestibular
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrical vestibular stimulation (n=15) administered for 12 weeks
Study: 34386216
Drug: Topical emollient
Normalized name: HPR Topical Emollient Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical emollient therapy with sunflower seed oil (SSO)
Study: 34629300
Drug: Docetaxel +
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel + Metformin (D+M)
Study: 34342746
Drug: Lurasidone (20-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (20-120 mg/day)
Study: 35323085
Drug: Triptorelin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (0.1 mg subcutaneous GnRH agonist)
Study: 35475155
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist therapy
Study: 34087831
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of dexmedetomidine
Study: 34087831
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.9% sodium chloride solution (control)
Study: 32799649
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to daily Occupational Performance approach™ (CO‐OP)
Study: 35264213
Drug: Green-MED diet
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green-MED diet (supplemented with 28g/day walnuts, daily polyphenol-rich green tea, and Mankai aquatic plant)
Study: 33186897
Drug: Collagen Peptides
Normalized name: CASTOR OIL 100 g in 100 mL TOPICAL OIL [Anyi Beauty Biotin With Collagen Peptides Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen Peptides (15 g/day)
Study: 33725433
Drug: High oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oxygen concentration (100% O2, non-rebreather mask, 8 L/min)
Study: 32004648
Drug: FMX103 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMX103 1.5% topical minocycline foam
Study: 34431238
Drug: Wait-list/no-treatment control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list/no-treatment control group
Study: 32173633
Drug: Dual trigger
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual trigger group (GnRH agonist and rHCG)
Study: 35924398
Drug: Non-ionic colloidal
Normalized name: NON-IONIC CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ionic colloidal silver solution rinse for 6 months as an adjunct to standard oral hygiene regimen
Study: 32690763
Drug: v-gel SGAD
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: v-gel SGAD
Study: 33231778
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) applied to wound surface for 5 minutes after incision
Study: 32076985
Drug: Individual acupuncture
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual acupuncture therapy
Study: 32076985
Drug: Group acupuncture
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group acupuncture therapy
Study: 35609328
Drug: FED (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FED (0.25 g·kg‐1 protein and 0.75 g·kg‐1 carbohydrate with 5% l‐[1‐13C]leucine)
Study: 35609328
Drug: EXFED (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXFED (0.25 g·kg‐1 protein and 0.75 g·kg‐1 carbohydrate with 5% l‐[1‐13C]leucine after resistance exercise)
Study: 35840300
Drug: Family doctor-led
Normalized name: Doctor's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family doctor-led intervention including usual care, medication reminder, 4-week plan, weekly phone interview, and monthly interview.
Study: 36207154
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication (multimodal analgesic solution)
Study: 32780742
Drug: Agent-based dynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent-based dynamic process with gendered status concerns
Study: 32780742
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group of agents less influenced by relative status rank
Study: 34861170
Drug: Pimavanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin (20 mg starting dosage, adjustable to 34 mg or 10 mg within the first 8 weeks, administered orally once daily)
Study: 35859621
Drug: Amino Acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino Acid Combination (AA) (3 g of L-arginine-hydrochloride and 8 g of L-citrulline-malate)
Study: 35859621
Drug: Green Tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green Tea Extract (GTE) (300 mg)
Study: 33177278
Drug: Ascidian-derived plasmalogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascidian-derived plasmalogen (1 mg as plasmalogen) for 12 weeks
Study: 33211738
Drug: Evidence-based practices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based practices (EBPs) in dispensing OTC medications
Study: 32929906
Drug: Percutaneous autogenous
Normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous autogenous cBMA+PRP injection
Study: 32929906
Drug: Percutaneous autogenous
Normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous autogenous bone marrow blood injection (Control)
Study: 36233611
Drug: Ellagic Acid
Normalized name: Ellagic acid
DrugBank: Ellagic acid (DB08846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ellagic Acid (500 mg orally twice a day for 12 weeks)
Study: 34967732
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve block (SSNB) in combination with intra-articular corticosteroid injection (IAI)
Study: 34967732
Drug: Intra-articular corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular corticosteroid injection (IAI) only
Study: 33449337
Drug: ALN-EX (effervescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN-EX (effervescent buffered solution of 70 mg alendronate)
Study: 33449337
Drug: ALN-T (alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN-T (alendronate tablets)
Study: 36471982
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine as adjuvant therapy
Study: 33934471
Drug: 4% capryloyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% capryloyl glycine and 1% glycine soy‐fermented extract cream (product A)
Study: 33934471
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (product B)
Study: 34516703
Drug: Naringenin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naringenin (100 mg capsules, twice a day for 4 weeks)
Study: 34516703
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo capsules, twice a day for 4 weeks)
Study: 35733127
Drug: Transdiagnostic cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic cognitive behavioral therapy (TCBT) - 10 sessions
Study: 33218555
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy and rehabilitation (PTR) combined with osteopathic management (OSTEO group)
Study: 33218555
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy and rehabilitation (PTR) only (PTR group)
Study: 35796739
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist regimen
Study: 35796739
Drug: Short GnRH
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short GnRH agonist regimen
Study: 33397139
Drug: Midazolam (0.045
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.045 mg/kg)
Study: 35298917
Drug: Levothyroxine (0.5-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (0.5-1.0 μg/kg bodyweight, orally once daily until the end of pregnancy)
Study: 35298917
Drug: Placebo (orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (orally once daily until the end of pregnancy)
Study: 32485325
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (pharmacy liaison to promote medication adherence).
Study: 36006011
Drug: Filgotinib vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib vs. intravenous vedolizumab
Study: 36006011
Drug: Filgotinib vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib vs. subcutaneous vedolizumab
Study: 34308834
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg generic solifenacin succinate tablet
Study: 34308834
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg solifenacin succinate tablets (vesicare)
Study: 35532908
Drug: Methylcobalamin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcobalamin (50 mg, intramuscular injection, twice weekly for 16 weeks)
Study: 35532908
Drug: Placebo (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intramuscular injection, twice weekly for 16 weeks)
Study: 34588198
Drug: Low-dose inhaled
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose inhaled corticosteroids (VDKA trial)
Study: 35933275
Drug: Inactivated quadrivalent
Normalized name: influenza virus vaccine, inactivated quadrivalent intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated quadrivalent influenza vaccine (IIV4) co-administered with the first dose of CoronaVac (C1 subgroup)
Study: 35933275
Drug: Inactivated quadrivalent
Normalized name: influenza virus vaccine, inactivated quadrivalent intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated quadrivalent influenza vaccine (IIV4) co-administered with the second dose of CoronaVac (C2 subgroup)
Study: 35933275
Drug: CoronaVac administered
Normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac administered 14 days after the first dose (S group)
Study: 32598699
Drug: Mechanical bacterial
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical bacterial lysate (MBL) added to conventional therapy for COPD, 3 cycles of 10 days therapy with 20-day intervals between them.
Study: 32598699
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy for COPD without MBL (control group).
Study: 34379277
Drug: Multimodal strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal strategies including clinician hypertension group‐based trainings, monthly clinician feedback reports, and monthly meetings with practice champions
Study: 33011586
Drug: In-person therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person therapy
Study: 35213754
Drug: Rumen-protected lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rumen-protected lysine (RPL) supplementation (80g daily from Day 21 before expected calving to parturition)
Study: 33641259
Drug: Pharmacogenomics guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenomics guided treatment (n=105)
Study: 33641259
Drug: Standard antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antidepressant treatment (n=108)
Study: 33962901
Drug: Academy of
Normalized name: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition indicators for the diagnosis of adult and pediatric malnutrition
Study: 36191334
Drug: Any analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any analgesic administration
Study: 36191334
Drug: Analgesic administration
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic administration in African American patients
Study: 36191334
Drug: Analgesic administration
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic administration in White patients
Study: 36191334
Drug: Analgesic administration
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic administration in Hispanic patients
Study: 34001002
Drug: M207 3.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: M207 3.8 mg (intracutaneous zolmitriptan)
Study: 32412986
Drug: TFP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFP block with 20 ml of 0.25% bupivacaine
Study: 36919514
Drug: d-amphetamine (AMPH;
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (AMPH; 20 mg)
Study: 36165603
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives and menstrual cycle phases
Study: 32019814
Drug: 1.8 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 µg of vitamin B12 daily for 6 months
Study: 32019814
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of folic acid daily for 6 months
Study: 32019814
Drug: Both vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vitamin B12 and folic acid daily for 6 months
Study: 33524593
Drug: Standard-volume plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-volume plasma exchange (SVPE), mean sessions 2.15 ± 1.42, median plasma volume replaced 5.049 L
Study: 35986323
Drug: Atosiban (6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (6.75 mg bolus intravenously 30 min before embryo transfer)
Study: 35986323
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline infusion)
Study: 33887486
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fibrosis grade and pancreatic texture
Study: 34958809
Drug: 0.5 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 Gy single session LDRT along with standard pharmacologic therapy
Study: 34958809
Drug: Standard pharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacologic therapy alone
Study: 33684595
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of meropenem 3 g/24 h
Study: 33684595
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of meropenem 1 g q8h
Study: 32509290
Drug: Sunflower seed
Normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower seed oil (SSO) treatment at 3 g/kg body weight three times daily for 10 days
Study: 32509290
Drug: Sunflower seed
Normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower seed oil (SSO) treatment